Tobias Zeller

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

A. Moosmann, M. von Bergwelt-Baildon, M. Peipp, 2022, Frontiers in Immunology.

Immunotherapeutic Targeting of Activating Natural Killer Cell Receptors and their Ligands in Cancer.

M. Peipp, Stefan Zielonka, K. Klausz, 2022, Clinical and experimental immunology.

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer

D. Schewe, R. Windisch, Tobias Zeller, 2023, Frontiers in immunology.

Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

M. Peipp, T. Valerius, K. Müller, 2024, HemaSphere.